Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- Check4 days agoChange DetectedThe page no longer displays links or sections for bladder cancer, related topics, and MedlinePlus Genetics, reducing navigational references to these topics on the study page.SummaryDifference0.2%

- Check12 days agoChange DetectedNew navigation items were added to the page: 'Bladder cancer' and a 'related topics' section featuring 'MedlinePlus Genetics', providing additional context and links to related resources.SummaryDifference0.2%

- Check19 days agoChange DetectedRevision note updated to v3.5.4, replacing v3.5.3 and signaling a minor update to the page's documentation.SummaryDifference0.1%

- Check26 days agoChange DetectedRemoval of items in the Related topics section, specifically Bladder cancer and MedlinePlus Genetics. This alters the navigation and topic tagging on the page, while the core study information remains unchanged.SummaryDifference0.2%

- Check33 days agoChange DetectedBladder cancer is added as a related topic on the page, and MedlinePlus Genetics is listed under related topics to link the study to broader cancer and genetics resources.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page’s footer/version label was updated to “Revision: v3.5.3,” and a related-topics section entry referencing “Bladder cancer” and “MedlinePlus Genetics” was removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.